Overcoming obstacles to repurposing for neurodegenerative disease
نویسندگان
چکیده
Repurposing Food and Drug Administration (FDA)-approved drugs for a new indication may offer an accelerated pathway for new treatments to patients but is also fraught with significant commercial, regulatory, and reimbursement challenges. The Alzheimer's Drug Discovery Foundation (ADDF) and the Michael J. Fox Foundation for Parkinson's Research (MJFF) convened an advisory panel in October 2013 to understand stakeholder perspectives related to repurposing FDA-approved drugs for neurodegenerative diseases. Here, we present opportunities on how philanthropy, industry, and government can begin to address these challenges, promote policy changes, and develop targeted funding strategies to accelerate the potential of FDA-approved repurposed drugs.
منابع مشابه
P184: Combination of Herbal Medicine and Nanomedicine: a Novel Therapeutic Target for Neurodegenerative Diseases
Inflammation is a pathologic condition that includes a wide range of diseases namely neurodegenerative diseases. Several natural anti-inflammatory components have been identified in plant extracts used in traditional medicine for the relief of inflammation. Herbal medicine is showing difficulty in crossing the blood-brain barrier (BBB). So that the ability to pass the BBB is the main concern fo...
متن کاملUsing Drugs as Molecular Probes: A Computational Chemical Biology Approach in Neurodegenerative Diseases
Neurodegenerative diseases including Alzheimer's disease are complex to tackle because of the complexity of the brain, both in structure and function. Such complexity is reflected by the involvement of various brain regions and multiple pathways in the etiology of neurodegenerative diseases that render single drug target approaches ineffective. Particularly in the area of neurodegeneration, att...
متن کاملCell specificity dictates similarities in gene expression in multiple sclerosis, Parkinson’s disease, and Alzheimer’s disease
Drug repurposing is an efficient approach in new treatment development since it leverages previous work from one disease to another. While multiple sclerosis (MS), Parkinson's disease (PD), and Alzheimer's disease (AD) are all neurodegenerative diseases of the central nervous system (CNS) and differ in many clinical and pathological aspects, it is possible that they may share some mechanistic f...
متن کاملP 155: The Roles of Microglia in Neurodegenerative Diseases
Microglia is a type of glial cell located throughout the central nervous system (CNS), which is sensitive to CNS injury and disease. Responsibility of microglia as the resident macrophage cells for injuries suggests that these cells have the potential to act as diagnostic markers of disease beginning or progression. Function of Microglia is strongly synchronized by the microenvironment of brain...
متن کاملRepurposing doxycycline for synucleinopathies: remodelling of α-synuclein oligomers towards non-toxic parallel beta-sheet structured species
Synucleinophaties are progressive neurodegenerative disorders with no cure to date. An attractive strategy to tackle this problem is repurposing already tested safe drugs against novel targets. In this way, doxycycline prevents neurodegeneration in Parkinson models by modulating neuroinflammation. However, anti-inflammatory therapy per se is insufficient to account for neuroprotection. Herein w...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 1 شماره
صفحات -
تاریخ انتشار 2014